Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Astellas Pharma Global Development Inc.
Sponsor

Astellas Pharma Global Development Inc.

United States 2375 Waterview Drive, 60062-6145, United States

About the sponsor

Research activity centers on gastric cancer, gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and related advanced solid tumors, with emphasis on tumors defined by CLDN18.2 expression and HER2-negative disease.

  • Gastric adenocarcinoma
  • Gastroesophageal junction adenocarcinoma
  • CLDN18.2-positive tumors
  • Metastatic pancreatic adenocarcinoma

The portfolio also includes studies in locally advanced unresectable and metastatic upper gastrointestinal disease.

About Specializations

Astellas Pharma Global Development Inc. runs clinical trials in conditions such as Adenocarcinoma gastric, Oesophageal adenocarcinoma, Acute myeloid leukaemia, Bladder cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

17 clinical trials

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Prostate cancer

Recruiting

A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Nephrogenic anaemia

Recruiting

Study on Roxadustat for Treating Anemia in Children with Chronic Kidney Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Epoetin Alfa
  • Sponsor:Astellas Pharma Global Development Inc.

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric

Not recruiting

Study on Zolbetuximab and mFOLFOX6 for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric

Not recruiting

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma gastric+1

Not recruiting

Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Astellas Pharma Global Development Inc.

Acute myeloid leukaemia

Not recruiting

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Acute myeloid leukaemia

Not recruiting

Study of Gilteritinib and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Astellas Pharma Global Development Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.